@article{acd6f1096d144ab9be9e99ffafb8a92d,
title = "Effectiveness of film as a health communication tool to improve perceptions and attitudes in multiple sclerosis",
abstract = "Background: Health communication tools like film are capable of reducing health disparities and could be effective in addressing negative illness perceptions of MS in Hispanics/Latinx. Objective: To test the feasibility of using a culturally appropriate short narrative film to examine illness perceptions overtime and attitudes in Hispanics/Latinx affected with MS. Methods: Participants were assigned to view a short narrative film (n = 130) or not (n = 106). The Brief Illness Perception Questionnaire (BIPQ) was used to examine illness perceptions at baseline, one and three months. Focus groups were conducted at 6 months. Measures of sociocultural integration were obtained. Individual group BIPQ domains were evaluated over time using paired sample t-test. Multivariate linear regression was used to examine predictors of BIPQ change. Results: A more positive perception of treatment (p < 0.0001) and understanding (p = 0.0003) were seen at 3 months for those exposed to film. Focus groups were effective in highlighting that the perceived disease prognosis, family support and awareness of MS contributes to attitudes. Exposure to film was found to be the strongest predictor (Beta:6.31, p = 0.01) of BIPQ change at three months. Conclusion: Our results provide support that a short narrative film of MS in Hispanics/Latinx is a feasible intervention to change perceptions of MS to a more positive view.",
keywords = "Latino/Hispanic/Latinx, Multiple sclerosis, attitudes, education, film, health literacy, illness perceptions",
author = "{on behalf of the ARHMS investigators} and Horacio Chiong-Rivero and Michael Robers and Andrea Martinez and Manrique, {Clara P.} and Astrid Diaz and Kelly Polito and Borna Vajdi and Chan Chan and Margaret Burnett and Delgado, {Silvia R.} and Angel Chinea and McCauley, {Jacob L.} and Lilyana Amezcua",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: L. Amezcua reports personal compensation for consulting for Biogen Idec, Novartis, Alexion Pharmaceuticals, Genentech, EMD Serono and AbbVie. Research support from the National MS Society, NIH NINDS, Bristol Myers Squibb Foundation, and Biogen Idec. Research for clinical trial participation from Genentech and Genzyme/Sanofi. S. Delgado reports personal compensation for consulting for Novartis. Research support through the University of Miami from NIH/NIDS, National MS Society and Novartis. A. Chinea is a speaker for Sanofi-Genzyme, Biogen, Teva, Novartis, Genentech, EMD Serono, and Alergan. M. Burnett is a speaker and/or consultant for Biogen, Novartis, EMD Serono and a trialist for Genentech and MedDay.M. Robers has received funding from the NMSS Sylvia Lawry.K. Polito has received funding from the NMSS clinical fellowship. H. Chiong-Rivero has received funding from the NMSS clinical fellowship. J. McCauley reports personal compensation for participation on advisory boards for Sanofi Genzyme. Research support from the National MS Society, NIH/NINDS, Bristol Myers Squibb Foundation, and Genentech. Rest of authors have nothing to disclose. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by NMSS (RG-1607-25324) (Amezcua), California Community Foundation (Amezcua), Biogen, Idec (008798) (Amezcua), and NIH/NINDS (R01NS096212) (McCauley). Publisher Copyright: {\textcopyright} The Author(s) 2021.",
year = "2021",
doi = "10.1177/2055217321995947",
language = "English (US)",
volume = "7",
journal = "Multiple Sclerosis Journal - Experimental, Translational and Clinical",
issn = "2055-2173",
publisher = "SAGE Publications Inc.",
number = "1",
}